| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 86.31 | 268.1% | 117.6% |
| Total Income | 88.79 | 187.2% | 122.6% |
| Expenditure | 71.48 | 246.6% | 81.0% |
| PBT | 17.30 | 68.2% | 8140.1% |
| Net Profit | 13.90 | 177.5% | 4642.6% |
| OPM | 18.83% | 0.66pp | 19.72pp |
| NPM | 15.65% | 0.55pp | 14.92pp |
| EPS | 2.15 | 179.2% | 4200.0% |
Fischer Medical Ventures Reports 123% YoY Surge in Total Income for Q2 FY26 — Strengthens Position in India’s Fast-Growing MedTech Sector
29 Oct 2025 · 29 Oct 2025, 01:04 pm
Summary
Fischer Medical Ventures Limited has announced its unaudited financial results for Q2 & H1 FY26, reporting a 122.64% YoY surge in total income and a 135.90% YoY increase in EBITDA. The net profit saw a significant increase of 4,659.63% YoY.
Key Highlights
- 1
123% YoY surge in total income for Q2 FY26
- 2
18.74% EBITDA in Q2 FY26
- 3
39.88% YoY increase in H1 FY26
- 4
1,280.74% YoY increase in EBITDA in H1 FY26
- 5
4,659.63% YoY surge in net profit for Q2 FY26
- 6
Acquired landmark mixed-use property in Malaysia to develop an Integrated Regional Healthcare Hub
- 7
Expand FMV’s presence across Southeast Asia through Public-Private Partnership in Indonesia
- 8
Launched High-Resolution Open MRI at Sunray Scans, Chennai
- 9
Installed PICA 0.35T Open MRI at STNM Hospital, Sikkim
- 10
Won first prize at SuperAl Genesis Global Competition
- 11
Recognized for Al-driven drug discovery platform (DTIGN)
- 12
Preparing SpinCare® FDA filing; outcome expected Q4 FY26
Management Comments
Mr. Ravindran Govindan
Chairman of Fischer Medical Ventures Limited
Q2 was a very strong quarter for Fischer, marking significant improvement across all operational and financial parameters. The steep rise in profitability reflects the scalability of our model, better product realization, and the growing acceptance of Fischers technology across India and overseas markets.
Informational and educational content only. Not investment advice.